Successful passive monitoring of early-stage Parkinson’s disease patient mobility in Phase I RG7935/PRX002 clinical trial with smartphone sensors
Objective: Smartphone-based assessments and sensors have the potential to enable remote, passive monitoring of gait and mobility in early-stage Parkinson’s disease (PD) patients. Such sensor…The tricyclic antidepressant medication nortriptyline inhibits alpha-synuclein accumulation, aggregation and toxicity in multiple in vitro and in vivo models.
Objective: Using preclinical models, assess the potential disease-modifying effects of nortriptyline (NOR) as a treatment in early Parkinson’s disease (PD). Background: PD and other synucleinopathies…Reproducibility of data-driven Parkinson’s disease subtypes for clinical research using a Delphi process for expert-based consensus.
Objective: To assess reproducibility of published data-driven PD subtype classification systems. Background: There is no consensus on which is the most robust PD subtype classification…Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
Objective: The S4 study aims to characterize the distribution of alpha-synuclein (aSyn) pathology in multiple tissues and body fluids within the same Parkinson’s disease (PD)…Impacts of CSF kynurenine pathway on neuroinflammaion in patients with Parkinson’s disease
Objective: To investigate the interaction between the KYN pathway and the neuroinflammation in PD. Background: In Parkinson's disease (PD), some pathologic mechanisms are reported such as mitochondrial dysfunction, inflammatory reaction and oxidative stress. Inflammatory cytokines are noticed as one of an important mediator of inflammatory reaction in the central nervous system (CNS). Kynurenine (KYN) pathway is also known to play an important role for degradation of oxidative stress in the CNS. Disproportion of KYN pathway can act neurotoxically and induce several neurological diseases including PD. In metabolites produced from this pathway, 3-hydroxykynurenine (3-HK) and quinolinic acid are as neurotoxic and kynurenic acid (KYNA) is neuroprotective. Methods: We could recruited 20 patients with PD (age; 57-80 y, median; 69.5 y) and 13 controls (age; 23-83 y, median; 75.0 y). Clinical severity was evaluated with Hoehn and Yahr staging.Samples of the cerebrospinal fluid (CSF) were obtained between 9:00 and 10:00AM after overnight bed-rest and before breakfast in PD patients. Control CSF were corrected from normal pregnant women on their lumbar anesthesia ante partum who had no neurologically abnormal condition confirmed by neurological examination and neuroimagings in advance. All CSF samples were promptly cryopreserved in a deep freezer (-80 ℃).CSF levels of KYN or 3-HK were measured using with the high-performance liquid chromatography coupled with the electrochemical detector. CSF levels of IL-6, IL-1β, TNF-α and IFN-γ were also measures using with an ELISA. Statistical analysis was performed and the significance level was set at p<0.05.This study was carried out after approval in our university ethical review board and written informed consents from all participants. Results: CSF levels of KYN in PD and control were 22.6 to 90.3 nM (median; 49.0 nM) and 9.5 to 51.4 nM (30.5 nM), respectively. CFS levels of 3-HK were 0.2 to 13.3 nM (4.25 nM) and 0.001 to 3.96 nM (1.55 nM), respectively. These were significantly higher in PD than in control (p<0.05). These were still statistically significant after normalization to CSF levels of triptophan（p<0.05).There was a positive correlation between the CSF levels of 3-HK and TNF-α (r=0.54,p=0.055). Conclusions: We could suggest that elevated CSF levels of KYN and 3-HK and positive correlation between 3-HK and TNF-α in patients with PD is associated with neuroinflammation in the CNS.Verticality Perception Differentially Correlates with Pisa Syndrome in Parkinson’s Disease
Objective: To elucidate the contribution of verticality misperception to the generation of Pisa syndrome (PS) in patients with Parkinson’s disease (PD). Background: PD patients with…Is the GBA2 a new modifier for Gauchers’s disease and GBA1-related Parkinson’s disease?
Objective: This study was performed to determine the pathological role of GBA2 in the central nervous system(CNS) in Gaucher’s disease (GD) and GBA1-related Parkinson’s disease…Motor effects induced by D1- or D2-like receptor agonists in experimental parkinsonism.
Objective: We set out to compare movement patterns induced by systemic administration of l-dopa versus D1- or D2-class DA receptor agonists in mice with unilateral…Relationship of metabolic markers in Parkinson’s disease
Objective: To investigate the relationship of obesity, Hypertension (HTN), Ischemic heart disease (IHD), Dyslipidemia (DLP), and Diabetes Mellitus (DM) with PD. Background: Parkinson’s disease (PD)…Mesencephalic astrocyte-derived neurotrophic factor reduces cell apoptosis via upregulating HSP70 in SHSY-5Y cells
Objective: The newest candidate growth factor for dopaminergic neurons is Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF). Signaling mechanisms by which MANF protects dopaminergic neurons from ER…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.